Shareholders of TenX Keane Acquisition, a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination with Citius Pharmaceutical’s oncology subsidiary.   The newly combined public company will continue to trade on the Nasdaq stock exchange and be renamed Citius Oncology Inc.   The transaction has been unanimously approved by the Board of Directors of both companies and Citius Pharma. Subject to certain contractual as well as custom...